ABT 애벗 래버러토리스 · Abbott Laboratories

뚜렷한 변화 없음 · 1개월 -2.5% · PER 33배.

종가$100.51
시가총액$1,815억
업종헬스케어
다음 실적 발표2026-10-21
PER33.5배
매출 성장(최근 4분기)+8.1%
영업이익률16%
애널리스트 순상향률-3.7%
목표가 상승여력+20%
공매도 거래 비중43%
유명 투자자 보유3곳
1년 수익률-20%

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibu

2026-10-21 기준 · 출처: SEC EDGAR, FINRA, yfinance · 정보 제공용이며 투자 권유가 아닙니다

같은 업종 종목